• Total revenue up 5% to US$8.483 billion
• NPAT up 6% to US$2.007 billion
• NPATA up 3% to US$2.074 billion

For the half year ended 31 December 2024, CSL reported total revenue of US$8.48 billion, up 5% (5% at constant currency) compared to the prior comparable period. Reported net profit after tax attributable to CSL shareholders (NPAT) was US$2.01 billion, up 6% (7% at constant currency). NPATA, which excludes impairment and amortisation of acquired intellectual property and non-recurring items, was US$2.07 billion, up 5% at constant currency. CSL Behring's total revenue was $5,743 million, up 10%, driven by strong growth in Immunoglobulin and Haemophilia product sales. CSL Seqirus' total revenue of $1,661 million was down 9% due to significantly lower immunisation rates, particularly in the US. CSL Vifor's total revenue was $1,079 million, up 6%. Research and development expenses were $646 million, down 4%, while selling and marketing expenses were $754 million, up 7%. CSL's balance sheet remains strong, with net assets of $20,546 million. The company has reaffirmed its previous guidance, with FY25 revenue growth anticipated to be approximately 5-7% over FY24 at constant currency, and NPATA expected to be in the range of $3.2 billion to $3.3 billion, representing growth of 10-13%.

For FY25, revenue growth is anticipated to be approximately 5-7% over FY24 at constant currency. CSL's NPATA for FY25 is anticipated to be in the range of approximately $3.2 billion to $3.3 billion at constant currency, representing growth over FY24 of approximately 10-13%.

The fundamentals of CSL's underlying business units are robust and CSL is in a strong position to deliver annualised double-digit earnings growth over the medium term. CSL's therapies continue to be valued by patients and healthcare systems around the world, as demonstrated by the continued growth of the core Ig franchise and the solid uptake of new product launches by CSL Vifor. CSL Behring will continue to focus on improving gross margins, aided by the expected completion of the RIKA roll-out across CSL Plasma. While the market conditions for CSL Seqirus remain challenging, the iron market growth remains strong and CSL Vifor is expected to maintain a leadership position.